RAPS.org needs your explicit consent to store browser cookies. If you don't allow cookies, you may not be able to use certain features of the web site such as personalized content. Please see our Privacy Policy for more information.

The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move
across top level links and expand / close menus in sub levels. Up and Down arrows will open main level
menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab
will move on to the next part of the site rather than go through menu items.

About the Regulatory Profession

The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.

Regulatory Code of Ethics

One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.

Regulatory Competency Framework

Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.

Regulatory Convergence

Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.

Italian Regulators Affirm Safety of Novartis' Vaccines

Posted 12 November 2012 | By

Italy's Agenxia Italiana del Farmaco (AIFA) has joined Canadian and Swiss regulators in affirming the safety of Novartis' Agrippal (alternately known as Agriflu) and Fluad after concerns were raised about the safety effects of a protein aggregation within vials of the vaccine.

The concerns were first brought to regulators' attention in late October 2012, leading several regulatory agencies-including those of Italy, Spain, Switzerland, Canada, Germany and France-to suspend the sale of the products or their import. No regulatory agency made note of any adverse event signals, but rather said they were taking action out of an abundance of caution.

"Health Canada has completed its review of safety information for Agriflu and Fluad and is releasing the two seasonal flu vaccines for immediate use," Canadian regulators wrote in a&nbsp;statement&nbsp;on 31 October. "Health care professionals in possession of these vaccines can start using them once again," it added. Switzerland's Swissmedic released a similar statement regarding the vaccine's safety and efficacy, noting it showed no effect on either.

At the time of those statements, AIFA said it was still awaiting the final results of its own testing, though it said its preliminary testing had been in line with Canadian and Swiss regulators' results.

Now, though, AIFA's results have been confirmed. In a 9 November 2012 statement, the agency said it had "removed the ban on the use of vaccines manufactured by Novartis V&amp;D."

"This was made ​​possible as a result of careful checks made ​​on the documentation produced by the Company in response to requests to conduct in-depth investigation of a possible lack of quality found in some batches of the vaccine and the concomitant analysis by [Novartis] and the National Institute of Health," AIFA said in a statement translated by Google Translate.

Italian regulators said the episode was indicative of the, "Extreme caution and rigor of the checks that are carried out on all vaccines, such that, even where there is found the remote possibility of the presence of a minimum quality defect, precautionary measures are readily adopted to protect public health concerns." Those measures extend to the whole production process, it added.

Other countries, including France, have since lifted their suspensions on the vaccine as well, but the product remains suspended in Spain and Germany for the time being.